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Dear Editor,  
 
Distinction of keratoacanthoma (KA) from squamous cell carcinoma (SCC) is challenging. 
Management is controversial, with some advocating prompt surgical excision and others 
monitoring to allow for spontaneous resolution1. The controversy is compounded by rare 
reports of metastasis2. And yet the benign natural history of KA is supported by various 
studies, including a systematic review of 455 cases with no cases of metastasis or death1, and 
observational studies confirming spontaneous resolution1. Unlike in SCC, perineural or 
venous invasion in KA is not associated with adverse outcome3,4. Comparative genomic 
hybridisation and DNA microarray studies indicate that KA and SCC are genetically 
distinct.5,6 Some have suggested that the rare reports of metastatic KA may have instead 
arisen from SCC development within KA3.  
 
An online 22-item questionnaire designed by dermatologists and researchers, ascertained 
clinicians’ views about KA and its management, previously observed outcomes and 
willingness to enrol patients into a proposed clinical trial. The questionnaire was circulated 
via the British Association of Dermatologists (BAD), the British Society for Dermatological 
Surgery (BSDS), Reconstructive Surgery Trials Network (RSTN), UK Dermatology Clinical 
Trials Network (UKDCTN) and the national trainee electronic mailing list. Of 223 
respondents 162 (73%) were consultants. Responses to a subset of questions were compared 
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between specialties (dermatology [n=152], dermatological surgery [n=48], and plastic 
surgery [n=21]) (chi-squared or Fisher’s exact test (IBM SPSS Version 22). 
 
While twenty-six (12%) respondents considered KA and SCC to be clinically and 
histologically indistinguishable, the majority (194, 87%) regarded them as distinct (13%) or 
likely distinct (74%). Only 28 (13%) felt that conservative management (e.g. clinical 
observation and/or shave excision) could be considered. Most (166,74%) felt that KA should 
be managed as for SCC, as spontaneous resolution cannot be reliably predicted nor SCC 
reliably excluded. Dermatological surgeons were more likely (23%) than dermatologists 
(10%) or plastic surgeons (0%) (p=0.03) to regard them as indistinguishable. 
 
Twenty-one (9%) reported that they had observed local recurrence of KA, while 4 (2%) 
reported having observed metastasis.  
 
A photograph of a typical KA-like lesion was presented with three scenarios of lesion 
behaviour (reducing in size/static/enlarging) over a hypothetical preceding four-week period. 
For each, respondents could choose multiple management options (see Table 1A). There were 
no statistically significant differences between specialties (24 tests all with p>0.05). In the 
case of the involuting scenario, around 35% selected clinical observation, and around a half 
excision. When the lesion was static or enlarging, surgical excision was favoured. 
 
The majority (74%, 166) reported not deferring surgery for KA-like lesions while 26% (57) 
reported doing so, with no significant between-specialty differences apparent (p=0.40). 
Comments indicated that even if not intended, deferral frequently occurs due to waiting lists. 
One hundred and forty-two (68%) indicated a willingness to routinely observe KA-like 
lesions if a clinical trial were to confirm spontaneous resolution in a proportion of cases 
(Table 2A – supplementary material).  
 One hundred and twenty-five (56%) declared that anatomical site did not influence 
management, although the clinical vignettes indicated a lower inclination to excise involuting 
lesions on the lower leg compared with the ear. 
Over a half  indicated willingness to enrol patients with KA-like lesions into a UK multi-
centre clinical trial (table 1b(i)). 
 
Around a half (Table 1Bii) were willing to enroll patients into a suggested  trial design  which 
incorporated a 4- to 5-week initial clinical observation period to establish the growth phase of 
the lesion, but ensuring risk minimisation by promptly excising all enlarging lesions within 
31/62 day NHS cancer targets. Table 1B).  
 
Suggested exclusion criteria included immunosuppression, genetic disorders (e.g. xeroderma 
pigmentosum), disputed clinical diagnosis, previous SCC, and high risk or cosmetically 
sensitive sites (Table 2B – supplementary material).  
 
Inclusion of an initial incisional biopsy reduced clinician willingness to enrol patients. 
Reasons cited included surgical capacity or duplication of surgery, and concerns over the 
adequacy of partial biopsy for histological KA diagnosis. (Table 2B – supplementary 
material). One respondent highlighted the possible confounding impact of biopsy, citing high 
regression rates of KA following incisional biopsy7. 
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For lesions static in size after 4-5 weeks’ observation, 70 (33%) were willing to shave excise, 
84 (40%) were not and 57 (27%) were uncertain (Table 1Biv). Comments highlighted 
concerns over potential under-treatment of SCC and uncertainty regarding adequacy of shave 
excision for histological diagnosis. Others indicated a preference for curettage. A proposal to 
randomise patients with static lesions to either shave or surgical excision did not increase 
recruitment willingness. (Table 1Bv).  
 
Ninety (41%) indicated their local histopathologists distinguish KA from SCC, 27 (12%) 
indicated that they do not and the remainder (101, 46%) noted variation. In a UK 
histopathology department survey, the ratio of coded SCC to KA varied from 2.5:1 to 139:1 
confirming widespread reporting variations8. In a clinical trial, centralised expert 
histopathologist review could overcome this issue. Of note, central review of SCC histology 
specimens led to reclassification as KA in up to 94.4% of cases in two phase II vemurafenib 
trials4.  
 
Our survey demonstrates significant clinical equipoise in the management of KA-like lesions 
amongst UK clinicians and confirms a willingness to enrol patients in a clinical trial, while 
highlighting the need to mitigate against under-treatment of any potential SCC within the trial 
design. 
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Table 1 
 
 (a) Management choices for KA-like lesions on the ear and leg 
Lesion status & 
location 
Treatment Approach  
N (%)† 
 
 Incisional 
biopsy 
Surgical 
excision 
Shave Clinical  
observation 
Reducing in size Ear 28 (13%) 123 (55%) 0 (18%) 75 (34%) 
  Leg 34 (15%) 96 (43%) 4 (24%) 80 (36%) 
No change in size 
for 4 weeks 
Ear 19 (9%) 195 (87%) 3 (10%) 9 (4%) 
Leg 25 (11%) 181 (81%) 0 (13%) 9 (4%) 
Increasing in size Ear 12 (5%) 207 (93%) 15 (7%) 0 (0%) 
14 (6%) 211 (95%) 15 (7%) 1 (0%) 
†Respondents could choose more than one treatment approach, thus across categories percentages can sum to 
>100% 
(b) Willingness to participate in UK multi-centre clinical study/trial, depending on trial design* 
Yes No               Unsure Total 
Responses 
General willingness  
to participate 
128 (58%) 24 (11%) 70 (32%) 222
b) Defined period of observation (4-5 
weeks), followed by:  
- Excision of enlarging lesions 
- Observation of involuting lesions 
106 (48%) 44 (20%) 71 (32%) 221
c) Prior incisional biopsy and defined 
period of observation (4-5 weeks):  
- Excision of enlarging lesions or with 
histology suggestive of SCC 
- Observation of involuting lesions with 
histology suggesting KA 
84 (39%) 74 (35%) 55 (26%) 213
d) As for b), but shave for static lesions 
(subsequent excision if recurrence, or if 
histology suggests SCC) 
70 (33%) 84 (40%) 57 (27%) 211
e) As for b), but static lesions randomised 
to either shave or excision 
(subsequent excision of shaved lesions if 
recurrence, or if histology suggests SCC) 
69 (33%) 75 (36%) 67 (32%) 211
*Figures rounded up to nearest %; may not add up to 100% 
 
 
 
